March 7th 2024
Tocilizumab-aazg (Tyenne; Fresenius Kabi) is the first approved biosimilar to tocilizumab (Actemra; Genentech) as both intravenous and subcutaneous.
Risks and Liabilities in Pharmacy Practice
1.0 Credit / Law
View More
Background and Key Concepts in Biosimilars: Improving Awareness and Addressing Common Concerns
1.0 Credit / Law
View More
Clinical Conversations With the Cancer Care Team: Striving for Equitable Access to Oral Anticancer Medications
1.5 Credits / Law, Oncology
View More
Child Abuse: Responsibilities and Protection of the Reporter
1.0 Credit / Law
View More
FDA Approves Abatacept With Calcineurin Inhibitor for Prophylaxis of Acute Graft Versus Host Disease
December 17th 2021Abatacept is also approved for adults with moderate to severe rheumatoid arthritis, active psoriatic arthritis, and moderate to severe polyarticular juvenile idiopathic arthritis for children 2 years of age and older.
Read More
Study: Certain Immunosuppressing Drugs Do Not Increase Risk for Contracting COVID-19
September 23rd 2020A recent study found that patients on immunosuppressive therapy for common skin and rheumatic diseases, such as psoriasis and rheumatoid arthritis, are not at an increased risk for contracting COVID-19.
Read More
American College of Rheumatology Releases Position Statement on Prior Authorization
March 31st 2020The American College of Rheumatology addresses the prior authorization requirement for some prescription medications, highlighting the significant burden this creates for patients and rheumatology professionals.
Read More
Class of Cancer Drugs May Have Potential as Chronic Obstructive Pulmonary Disease Treatment
January 17th 2020The ErbB inhibitors, gefitinib, erbstatin, and tryphostin AG825, inhibit a cell signaling process controlling the death-rate of neutrophils, immune cells, which cause damage to the lungs.
Read More
New Treatment for Rheumatoid Arthritis Granted FDA Approval
August 19th 2019Officials with the FDA have approved AbbVie’s upadacitinib (Rinvoq) 15 mg, once-daily oral Janus kinase (JAK) inhibitor, for the treatment of adults with moderately to severely active rheumatoid arthritis (RA) who have had an inadequate response or intolerance to methotrexate (MTX-IR).
Read More
FDA: Elevated Risk of Blood Clots in Lungs, Death in RA Patients on Higher Dose Tofacitinib
February 27th 2019A 10 mg twice daily dose of tofacitinib (Xeljanz, Xeljanz XR, Pfizer) used in patients with rheumatoid arthritis increased the risk of blood clots in the lungs and death in a safety clinical trial.
Read More